Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

• 18 years or older
• chemotherapy naive, histologically high grade soft tissue sarcoma that is considered to be operable
• tumor greater than 5 cm in longest dimension
• life expectancy of at least 6 months
• Zubrod performance status of 0-2
• signed informed consent

• adequate bone marrow function defined by:

  1. absolute peripheral granulocyte count of >1500 cells/mm\^3
  2. hemoglobin >8.0 g/dl
  3. platelet count >100,000/mm\^3
  4. absence of a regular red blood cell transfusion requirement

• adequate hepatic function defined by:

  1. total bilirubin \<1.5 x upper limit of normal (ULN)
  2. AST, ALT and alkaline phosphatase all not more than 2.5 x ULN

• adequate renal function defined by:

  1. serum creatinine \<1.5 x ULN
• negative pregnancy test for women of child bearing potential
• willingness to use effective contraception while on treatment and for 3 months thereafter

Exclusion Criteria:

• Multiple metastases (patients with 5 or fewer oligometastases that could be resectable are eligible)
• Pregnant women or nursing mothers
• concurrent chemotherapy or radiation therapy
• severe medical problems (at the discretion of the investigator)
• history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
• symptomatic brain metastases
• cirrhosis
• dermatofibrosarcoma protuberans (DFSP), embryonal rhabdomyosarcoma or alveolar soft part sarcoma (ASPS)